<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787293</url>
  </required_header>
  <id_info>
    <org_study_id>08-010P</org_study_id>
    <nct_id>NCT00787293</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients</brief_title>
  <acronym>PTOLEMY-2</acronym>
  <official_title>A Multi-center Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viacor</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medifacts International Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Viacor</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement in heart failure with moderate to severe mitral regurgitation using a
      percutaneously delivered implantable device.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Company ended operations January 2011
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from MACE at 30 days post-procedure and quantitative MR reduction at 6 months</measure>
    <time_frame>30 days to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of patients experiencing procedure or device-related adverse events</measure>
    <time_frame>30 days to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical procedural success: % of patients maintaining a reduction of mitral annulus A/P dimension, sustained MR reduction, and decrease in left ventricular dimensions to specified degrees</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status: % of treated patients exhibiting improvements in defined QoL parameters</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant</intervention_name>
    <description>Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functional MR 2+ - 4+

          -  Symptomatic heart failure, NYHA Class II to IV

          -  LVEF &gt; 25% or &lt; 50% OR dilated mitral annulus &gt; 30mm

        Exclusion Criteria:

          -  MR of organic origin

          -  Severe mitral leaflet tethering

          -  History of MI or PCI within 60 days of study procedure

          -  Inability to walk a minimum of 100 meters in 6 minutes

          -  Significant left main stenosis or proximal circumflex stent

          -  Indication of non-patent CSO or discontinuous CS-GCV-AIV

          -  Bi-ventricular with leads in CS or other devices impeding device placement

          -  Severe aortic valvular disease

          -  Chronic corticosteroid use other than &lt; 20mg prednisone for arthritis

          -  Significant co-morbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Sack, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Schwabing, Staedtisches Klinikum Muenchen GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rainer Hoffmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>R-WTH Universitätsklinikum Aachen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis Cardiovasculair Ondrezoek Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>B-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Klinicke a Experimentalni Mediciny</name>
      <address>
        <city>Prague</city>
        <zip>1958/9</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheinisch-Westfalische Technische Hochschule Universitaetsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabeteszentrum Nordrhein-Westfalen / Ruhr University of Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>D-32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Duisburg-Essen Westdeutsches Herzzentrum Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center Frankfurt Sankt Katharinen</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert-Ludwigs-Universitat Freiburg Mediziniche Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <zip>D-79095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtische Klinikum Karlsruhe GmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwabing Städtisches Klinikum München GmbH</name>
      <address>
        <city>München</city>
        <zip>D-80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxcentrum Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>N-3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>N-3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.viacorinc.com</url>
    <description>company website including information in Dutch, German, and French</description>
  </link>
  <reference>
    <citation>Fukuda S, Gillinov AM, Liddicoat JR, Saracino G, Hayase M, Cohn WE, Schneider CW, Shiota T. Maintenance of geometric alterations associated with percutaneous mitral valve repair: real-time three-dimensional echocardiographic assessment in an ovine model. J Heart Valve Dis. 2008 May;17(3):276-82.</citation>
    <PMID>18592924</PMID>
  </reference>
  <reference>
    <citation>Daimon M, Gillinov AM, Liddicoat JR, Saracino G, Fukuda S, Koyama Y, Hayase M, Cohn WE, Ellis SG, Thomas JD, Shiota T. Dynamic change in mitral annular area and motion during percutaneous mitral annuloplasty for ischemic mitral regurgitation: preliminary animal study with real-time 3-dimensional echocardiography. J Am Soc Echocardiogr. 2007 Apr;20(4):381-8.</citation>
    <PMID>17400117</PMID>
  </reference>
  <reference>
    <citation>Dubreuil O, Basmadjian A, Ducharme A, Thibault B, Crepeau J, Lam JY, Bilodeau L. Percutaneous mitral valve annuloplasty for ischemic mitral regurgitation: first in man experience with a temporary implant. Catheter Cardiovasc Interv. 2007 Jun 1;69(7):1053-61.</citation>
    <PMID>17525965</PMID>
  </reference>
  <reference>
    <citation>Daimon M, Shiota T, Gillinov AM, Hayase M, Ruel M, Cohn WE, Blacker SJ, Liddicoat JR. Percutaneous mitral valve repair for chronic ischemic mitral regurgitation: a real-time three-dimensional echocardiographic study in an ovine model. Circulation. 2005 May 3;111(17):2183-9. Epub 2005 Apr 25.</citation>
    <PMID>15851597</PMID>
  </reference>
  <reference>
    <citation>Liddicoat JR, Mac Neill BD, Gillinov AM, Cohn WE, Chin CH, Prado AD, Pandian NG, Oesterle SN. Percutaneous mitral valve repair: a feasibility study in an ovine model of acute ischemic mitral regurgitation. Catheter Cardiovasc Interv. 2003 Nov;60(3):410-6.</citation>
    <PMID>14571496</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <last_update_submitted>February 10, 2011</last_update_submitted>
  <last_update_submitted_qc>February 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Katharine M Stohlman</name_title>
    <organization>Viacor, Inc.</organization>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Percutaneous</keyword>
  <keyword>Coronary sinus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

